Outlook for patients with CAP worldwide
ZINFORO® offers an efficacious and potent treatment for patients with CAP.1,2,*
Consistently active against common causative pathogens, delivering positive outcomes
*REACH was a retrospective, observational study relating to the current treatment practice in 10 European countries (Belgium, France, Germany, Greece, Italy, the Netherlands, Portugal, Spain, Turkey and the United Kingdom).
REACH does not include data specific to ZINFORO®.
In REACH, ‘initial treatment modification’ was defined as the need for a change in the first-line antibiotic treatment due to insufficient response, adverse reaction, interaction with other drugs, non-suitability of the initial antibiotic based on the results of microbiological tests and changes to, or additions of, new agents in a subsequent line (alone or in combination). Patient death or streamlining (de-escalation of treatment to narrow-spectrum antibiotics upon patient improvement or confirmed microbiological diagnosis) was not included within the definition of initial treatment modification.5
†There is no experience with ZINFORO® in the treatment of CAP in the following patient groups: The immunocompromised, patients with severe sepsis/septic shock and severe underlying lung disease; patients with PORT risk Class V, and/or CAP requiring ventilation at presentation, CAP due to MRSA and patients requiring intensive care. Caution is advised when treating such patients.8
CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infection; MoA, mechanism of action; MRSA, methicillin-resistant Staphylococcus aureus; PORT, Pneumonia Patient Outcomes Research Team; REACH, REtrospective Study to Assess the Clinical Management of Patients With Moderate-to-Severe cSSTI or CAP in the Hospital Setting.
References:
Please click the Prescribing Information link to view the safety and adverse events information of ZINFORO®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ZFO-IND-0417 June 2022
Example
Simple dosing with a flexible infusion time
Proven clinical efficacy in patients with
CAP and cSSTI
Safety profile consistent with other cephalosporins
ZINFORO® in the treatment of CAP and cSSTI
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.